-+ 0.00%
-+ 0.00%
-+ 0.00%

Trevi Therapeutics Q2 FY26 net loss widens to $17.8 million

PUBT·08/06/2026 20:31:08
Listen to the news
Trevi Therapeutics Q2 FY26 net loss widens to $17.8 million
  • Trevi Therapeutics posted a GAAP net loss of USD 17.8 million, widening from a USD 12.3 million loss a year earlier.
  • GAAP R&D expenses rose to USD 15.2 million from USD 9.4 million, due to higher clinical development spending across multiple studies.
  • GAAP G&A expenses increased to USD 5.4 million from USD 4.3 million, while other income climbed to USD 2.7 million from USD 1.4 million.
  • Cash, cash equivalents, marketable securities totaled USD 318.9 million; Trevi expects runway into 2030, funding IPF-related chronic cough through potential FDA approval.
  • Phase 3 OCEAN-1 began; OCEAN-2 is slated for Q3 2026, with topline data expected in H2 2027 and OCEAN-1 topline in H1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805279) on August 06, 2026, and is solely responsible for the information contained therein.